About Forty51 Ventures
Forty51 Ventures is a venture capital firm founded in 2022. It is primarily based out of Basel, Switzerland. As of Apr 2026, Forty51 Ventures is an active investor, having invested in 4 companies, with 1 new investment in the last 12 months. It primarily invests in Seed round in Switzerland based startups. Its investments are spread across Life Sciences sector. Most recently it participated in the $***** Seed round of Ferrosa Therapeutics Forty51 Ventures has team of 3 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed
Portfolio Soonicorns
Deals in last 12 months
Forty51 Ventures' List of All Investments
Forty51 Ventures has a portfolio of 4 companies. Their most notable investments are in Allegria Therapeutics and Mosanna Therapeutics.Their portfolio spans across and Switzerland. They have invested in Life Sciences, across Seed stage. Here is the list of all investments by Forty51 Ventures:
Developer of therapeutics for allergy and inflammatory diseases. The company is working on RNA processing and the discovery of peptide-based therapeutics for cell-mediated diseases such as allergy and inflammatory conditions.
Key facts about Allegria Therapeutics
- Founded Year: 2023
- Location: Basel (Switzerland)
- Stage: Seed
- Total Funding till date: $8.6M
- Employee Count: 3 as on Jul 31, 2026
- Investors: ALK-Abello, Lichtsteiner Foundation and 2 Others
- Latest Funding Round: Seed, Dec 11, 2025, $*****
- Highlight: Editors' Pick
Developer of small molecule therapeutics for sleep apnea. It offers a lead candidate MOS-118 a targeted precision medicine that is based on the cardiometabolic impact on obstructive sleep apnea.
Key facts about Mosanna Therapeutics
- Founded Year: 2022
- Location: Basel (Switzerland)
- Stage: Series A
- Total Funding till date: $80M
- Employee Count: 15 as on Jul 31, 2026
- Investors: EQT, Norwest and 6 Others
- Latest Funding Round: Series A, Jun 09, 2025, $*****
- Highlight: Editors' Pick
Developer of therapuetics for auto-immune diseases. It offers PIM kinase inhibitors which provide anti-inflammatory effect for the tteatment of glomerulonephritis, rheumatoid arthritis and inflammatory bowel diseases.
Key facts about Mysthera Therapeutics
- Founded Year: 2023
- Location: Basel (Switzerland)
- Stage: Seed
- Total Funding till date: $3.5M
- Investors: Forty51 Ventures
- Latest Funding Round: Seed, Aug 21, 2023, $*****
- Highlight: Editors' Pick
Developer of bispecific antibodies treating anemia associated with chronic inflammation. These biologics target multiple pathways involved in iron regulation and red blood cell production. The therapeutic approach aims to address resistance to existing treatments in patients with kidney disease, cancer, and autoimmune conditions. The molecules are engineered for extended half-life to facilitate infrequent subcutaneous administration.
Key facts about Ferrosa Therapeutics
- Founded Year: 2026
- Location: Switzerland
- Stage: Seed
- Total Funding till date: $3.5M
- Investors: Forty51 Ventures
- Latest Funding Round: Seed, Apr 23, 2026, $*****
Forty51 Ventures' Year-on-Year Investment Trends
Forty51 Ventures has invested in 4 companies over the last 4 years, with an average of 1 new investment annually in the last 3 years. In 2025, it made 2 investments, while as of Apr 2026, it has made 1 investment in this year. Its most recent first time investment was in Ferrosa Therapeutics and most recent follow-on round was in Allegria Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 0 | 2 | 2 |
2024 | 1 | 0 | 1 |
2023 | 1 | 1 | 2 |
2022 | 1 | 0 | 1 |
Forty51 Ventures' Investments by Stage
Forty51 Ventures has made 4 investments in Seed stage with an average round size of $3.5M.Forty51 Ventures' Investments by Sector
Forty51 Ventures has a portfolio focused on Life Sciences. Notably, it has invested in 4 Enterprise (B2B) companies and 4 Tech companies.Forty51 Ventures' Investments by Geography
Forty51 Ventures has made most investments in Switzerland (4).Forty51 Ventures' recent investments
Forty51 Ventures has made 1 investments in 2026 so far - Ferrosa Therapeutics.Here are the most recent investments by Forty51 Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 23, 2026 | Switzerland | Seed | 5749 | - | |
Dec 11, 2025 | Switzerland | Seed | 9845 | [+2] | |
Jun 09, 2025 | Switzerland | Series A | 2966 | [+6] | |
May 06, 2024 | Switzerland | Seed | 3632 | - | |
Aug 21, 2023 | Switzerland | Seed | 7145 | - |
Team profile of Forty51 Ventures
Forty51 Ventures has a team of 3 members including 2 Partners located in France and Switzerland. Forty51 Ventures' team does not sit on the board of any company as of now.Co-investors of Forty51 Ventures
Over the past 4 years, 10 investors have co-invested in Forty51 Ventures's portfolio companies. This includes only funds.
- Invested after Forty51 Ventures: A total of 10 investors have invested in Forty51 Ventures's portfolio after their investments. Top Investors include ALK-Abello (1 company), Hlc Fund (1 company) and Lichtsteiner Foundation (1 company).
Recent News related to Forty51 Ventures
•
Biotech FERROSA raises USD 3.5 Million FinancingStartupticker•Apr 29, 2026•Ferrosa Therapeutics, Forty51 Ventures
•
Allegria Therapeutics Raises $5.1M in Seed Extension FundingFinSMEs•Dec 11, 2025•Allegria Therapeutics, ALK-Abello, Lichtsteiner Foundation, Hlc Fund and 1 other
•
Mosanna Therapeutics Launches with $80 Million for Obstructive Sleep Apnea Nighttime Nasal SprayPR Newswire•Jun 09, 2025•Mosanna Therapeutics, Pivotal Life Sciences, EQT, Broadview Ventures and 2 others
•
•
Basel-based Allegria Therapeutics Raised $3.5 Million Seed RoundSilicon Valley Journals•May 06, 2024•Allegria Therapeutics, Forty51 Ventures
•
Mysthera Therapeutics Raises $3.5M in Seed FundingFinSMEs•Aug 22, 2023•Mysthera Therapeutics, Forty51 Ventures
•
•
FORTY51 Ventures Announces the First Close of Fund I and its First InvestmentPR Newswire•Jul 18, 2022•Forty51 Ventures
•
